ADHERENCE AND PERSISTENCE OF PCSK9 INHIBITORS IN CLINICAL PRACTICE: THE REAL-WORLD ITALIAN EXPERIENCE (AT-TARGET-IT STUDY)

被引：0

作者：

Marzano, Federica ^{[1
]}

Basile, Christian ^{[2
]}

Paolillo, Stefania ^{[2
]}

Cesaro, Arturo ^{[3
]}

Buonocore, Davide ^{[2
]}

Asile, Gaetano ^{[2
]}

Abbate, Vincenza ^{[2
]}

Vicidomini, Francesca ^{[2
]}

Spaccarotella, Carmen Anna Maria ^{[2
]}

Spirito, Giulio ^{[4
]}

Maloberti, Alessandro ^{[5
,6
]}

Iannuzzo, Gabriella ^{[7
]}

Ciccone, Marco Matteo ^{[8
]}

D'alleva, Alberto ^{[9
]}

Corleto, Antonella ^{[10
]}

Brunetti, Natale Daniele ^{[11
]}

Indolfi, Ciro ^{[12
]}

Gargiulo, Paola ^{[2
]}

Perrone-filardi, Pasquale ^{[2
]}

机构：

[1] IRCCS Synlab Sdn, Naples, Italy

[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy

[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Caserta, CE, Italy

[4] Eboli Battipaglia Roccadaspide Maria Ss Addolorat, Emergency Dept, Div Cardiol, Eboli, Italy

[5] Asst Gom Niguarda, Div Cardiol 4, Cardioctr De Gasperi, Milan, Italy

[6] Bicocca Univ, Milan, Italy

[7] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[8] Univ Bari, Sch Cardiol, Bari, Italy

[9] Santo Spirito Hosp, Ccu Intervent Cardiol, Pescara, Italy

[10] Asl Torino 3, Rivoli Infermi Hosp, Turin, Italy

[11] Policlin Riuniti Univ Hosp, Cardiothorac Dept, Foggia, Italy

[12] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy

来源：

EUROPEAN HEART JOURNAL SUPPLEMENTS | 2022年 / 24卷

关键词：

D O I：

10.1093/eurheartjsupp/suac121.706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

555

引用

页数：1

共 50 条

[21] Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records
Barbati, Giulia
Gregorio, Caterina
Scagnetto, Arjuna
Indennidate, Carla
Cappelletto, Chiara
Di Lenarda, Andrea
PLOS ONE, 2024, 19 (08):
[22] PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
Altschmiedova, Tereza
Todorovova, Veronika
Snejdrlova, Michaela
Satny, Martin
Ceska, Richard
CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (05) : 357 - 363
[23] PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
Tereza Altschmiedová
Veronika Todorovová
Michaela Šnejdrlová
Martin Šatný
Richard Češka
Current Atherosclerosis Reports, 2022, 24 : 357 - 363
[24] EFFICACY OF PCSK9 INHIBITORS IN THE CLINICAL PRACTICE. FIRST YEAR EXPERIENCE
Navarro, G.
Fuentes, C.
Bellon, S.
Fernandez De Velasco, D.
Casas, M.
Guijarro, C.
ATHEROSCLEROSIS, 2018, 275 : E233 - E233
[25] PCSK9 inhibitors in clinical practice: Delivering on the promise?
Stoekenbroek, Robert M.
Hartgers, Merel L.
Rutte, Roger
de Wijer, Douwe D.
Stroes, Erik S. G.
Hovingh, G. Kees
ATHEROSCLEROSIS, 2018, 270 : 205 - 210
[26] JCL roundtable: PCSK9 inhibitors in clinical practice
Brown, W. Virgil
Moriarty, Patrick M.
McKenney, James M.
JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (01) : 5 - 14
[27] PCSK9 inhibitors in clinical practice: Expectations and reality
Reiner, Zeljko
ATHEROSCLEROSIS, 2018, 270 : 187 - 188
[28] Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
Volkova, S. Yu.
Boyarskaya, L. A.
Toropygin, P. Yu.
Morozov, I. A.
Boyarskaya, E. A.
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2023, 19 (01) : 43 - 49
[29] Real-World Patient Profiles and Lipid-Lowering Efficacy of PCSK9 Inhibitors
Ma, Tiantian
Huang, Fengmei
Yu, Qiuyan
Chui, Celine S. L.
Chen, Peiling
Wong, Ian Chi Kei
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 232 - 233
[30] Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
Uno-Eder, Kiyoko
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2023, 30 (09) : 1106 - 1107

← 1 2 3 4 5 →